Drug Trial Radar · NCT06517914
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
94
Actual
Start
Jul 29, 2024
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Yuhan CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of YH35995
Conditions
- Healthy Participants
Interventions
YH35995Drug
Oral administration of YH35995
PlaceboDrug
Oral administration of Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Part A, B] Treatment-emergent adverse events (TEAEs)Time frame: Part A: Day1-150, Part B: Day1-232
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHA Bundang Medical Center
Seongnam, Bundang-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.